Pancreatic Cancer Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

Neoadjuvant Therapy

A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Description: This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery.

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 to 75 y/o, with a histologically or cytologically proven pancreatic adenocarcinoma; histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible

Status

Contact site for study status

Contacts

Laurel Brechtel, 415-600-1654

Adjuvant Therapy

 A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma

Description: This randomized phase II-R/III trial studies gemcitabine hydrochloride with or without erlotinib hydrochloride followed by the same chemotherapy regimen with or without radiation therapy and capecitabine or fluorouracil in treating patients with pancreatic cancer that was removed by surgery.

Investigators

  • NCI - National Cancer Institute
     

Eligibility Requirements

Subjects, 18 years and older, with histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy
 

Status

Contact site for study status

Contacts

Laurel Brechtel, 415-600-1654

Metastatic Pancreatic Cancer

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer

Description: This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic cancer that has come back after a period of improvement (metastatic).
 

Investigators

  • NCI - National Cancer Institute
     

Eligibility Requirements

Subjects, 18 y/o and older, who have histologically or cytologically documented pancreatic adenocarcinoma. Patients with pancreatic neuroendocrine tumors, lymphoma of the pancreas, or ampullary cancer are not eligible
 

Status

Contact site for study status
 

Contacts

Laurel Brechtel, 415-600-1654

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Description: The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with nab-paclitaxel plus gemcitabine (AG treatment), in participants with hyaluronan (HA)-high Stage IV previously untreated pancreatic ductal adenocarcinoma (PDA). Participants will be randomized in a 2:1 ratio to PAG or AG treatment.

Investigators

Eligibility Requirements

Subjects, 18 y/o and older, who have stage IV pancreatic ductal adenocarcinoma (PDA) with histological confirmation of PDA via archived or fresh core biopsy of either the primary tumor or 1 metastatic site

Status

Active and open to enrollment

Contacts

Laurel Brechtel, 415-600-1654

 

A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX

Description: This is a randomized phase II multi-institution prospective open label study in which up to 90 subjects with metastatic, locally advanced unresectable or recurrent pancreatic cancer who previously received treatment with chemotherapy with FOLFIRINOX or FOLFIRINOX-like regimen

Investigators

  • Stephanie Jeske, MD

Eligibility Requirements

Subjects 18 y/o and older, with recurrent, locally advanced unresectable or metastatic adenocarcinoma of the pancreas who have progressed after primary therapy with FOLFIRINOX or FOLFIRINOX-like regimen or were intolerant of it

Status

Active and open to enrollment

Contacts

Laurel Brechtel, 415-600-1654

 

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Description: This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared with combination chemotherapy alone in treating patients with newly diagnosed pancreatic cancer that has spread to other places in the body

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 to 75 y/o, who have newly diagnosed, untreated metastatic histologically or cytologically documented pancreatic adenocarcinoma; patients must not have known history of brain metastases

Status

Please contact site for study status

Contacts

Laurel Brechtel, 415-600-1654

 

 

Pancreatic Neuroendocrine Tumors

Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

Description: This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects 18 y/o and older, who have a locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma of the gastrointestinal (GI) tract

Status

Please contact site for study status

Contacts

Laurel Brechtel, 415-600-1654

 

Non-Metastatic Pancreatic Cancer

Title: Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas

Description: The purpose of this study is to compare any good and bad effects of using chemotherapy compared to chemotherapy and radiation prior to surgery
 

Investigators

  • NCI - National Cancer Institute
     

Eligibility Requirements

Subjects, 18 y/o and older, with cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate process

Status

Contact site for study status

Contacts

Laurel Brechtel, 415-600-1654

A Randomized Phase II Study of Perioperative mFolfironix Versus Gemcitabine/Nab-paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Description: This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery

Investigators

  • NCI - National Cancer Institute

Eligibility Requirements

Subjects, 18 to 75 y/o, who have histologically or cytologically proven pancreatic adenocarcinoma; histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible

Status

Please contact site for study status

Contacts

Laurel Brechtel, 415-600-1654